Physicochemical Properties
| Molecular Formula | C41H55N7O9 |
| Molecular Weight | 789.9169 |
| Exact Mass | 789.406 |
| CAS # | 72122-62-4 |
| Related CAS # | β-Casomorphin, bovine TFA |
| PubChem CID | 121946 |
| Appearance | White to off-white solid powder |
| Density | 1.32g/cm3 |
| Boiling Point | 1170.5ºC at 760 mmHg |
| Flash Point | 661.7ºC |
| Index of Refraction | 1.607 |
| LogP | 2.38 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 16 |
| Heavy Atom Count | 57 |
| Complexity | 1450 |
| Defined Atom Stereocenter Count | 7 |
| SMILES | CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)N |
| InChi Key | RKYJTDSQXOMDAD-JKXTZXEVSA-N |
| InChi Code | InChI=1S/C41H55N7O9/c1-3-25(2)35(41(56)57)45-38(53)32-13-7-19-46(32)34(50)24-43-36(51)31-12-8-21-48(31)40(55)30(23-26-10-5-4-6-11-26)44-37(52)33-14-9-20-47(33)39(54)29(42)22-27-15-17-28(49)18-16-27/h4-6,10-11,15-18,25,29-33,35,49H,3,7-9,12-14,19-24,42H2,1-2H3,(H,43,51)(H,44,52)(H,45,53)(H,56,57)/t25-,29-,30-,31-,32-,33-,35-/m0/s1 |
| Chemical Name | (2S,3S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | After 8 hours of treatment, mucin secretion in DHE cells is stimulated by bovine beta-casomorphin (0.1 μM; 30 minutes to 24 hours) [2]. Increased rMuc2 and rMuc3 mRNA levels are induced by β-casomorphin, bovine (0.1 μM; 24 hours) [2]. β-Casomorphin, bovine does not modify rMuc1, rMuc4, and rMuc5AC expression [2]. Human HT29-MTX cells are stimulated to secrete mucin and express MUC5AC by bovine β-casomorphin (0.1 μM; 24 hours) [2]. |
| ln Vivo | Bovine β-casomorphin (7.5×10−6 mol/day/kg; gavage; for 30 days) raises plasma insulin and lowers plasma glucagon in diabetic rats [3]. β-Casomorphin, bovine (7.5×10−6 mol/day/kg; ig; for 30 days) modifies the alterations of SOD, GPx, T-AOC, MDA and H2O2 in the kidneys of diabetic rats [3]. Bovine β-casomorphin (7.5×10−6 mol/day/kg; gavage; for 30 days) lowered MDA (significant) and H2O2 (non-significant) levels in the kidney compared with diabetic rats [3]. β-Casomorphin, bovine (7.5×10−6 mol/day/kg; ig; for 30 days) reduced the high-glucose-induced decrease in SOD and GPx activities and the increase in MDA content in NRK-52E cells [ |
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (200 g±10 g) [3] Doses: 7.5×10−6 mol/day/kg Route of Administration: po (oral gavage); 30 days Experimental Results: Diabetic rats Plasma insulin increases and plasma glucagon decreases. |
| References |
[1]. Opioid activities of beta-casomorphins. Life Sci. 1981 Apr 27;28(17):1903-9. [2]. β-casomorphin-7-7 regulates the secretion and expression of gastrointestinal mucins through a μ-opioid pathway. Am J Physiol Gastrointest Liver Physiol. 2006 Jun;290(6):G1105-13. [3]. The protective effects of beta-casomorphin-7 against glucose -induced renal oxidative stress in vivo and vitro. PLoS One. 2013 May 3;8(5):e63472. |
Solubility Data
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~126.60 mM) H2O : ≥ 50 mg/mL (~63.30 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (3.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 25 mg/mL (31.65 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2660 mL | 6.3298 mL | 12.6595 mL | |
| 5 mM | 0.2532 mL | 1.2660 mL | 2.5319 mL | |
| 10 mM | 0.1266 mL | 0.6330 mL | 1.2660 mL |